Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board



    LAVAL, QC, Oct. 15 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB), is pleased to announce the
appointment of a dynamic new Scientific Advisory Board (the "Advisory Board"),
comprised of 5 renowned scientists.
    Neptune believes that the combined knowledge and experience of the new
members of the Advisory Board will significantly contribute to Neptune's
scientifically driven growth. Neptune feels privileged to build its new
Scientific Advisory Board with a group of such distinguished scientists.

    
    a. Steven E. Nissen, M.D., MACC, is the Chairman of the Cleveland Clinic
       Department of Cardiovascular Medicine, and Immediate Past President,
       American College of Cardiology, Washington, DC. He previously served
       as the Medical Director of the Clinic's Cardiovascular Coordinating
       Center. Dr. Nissen has stipulated that he receive no personal
       compensation for participation in the Advisory Board and that any
       consulting fees be paid directly to charity.
    b. Magdy M. Abdel-Malik, Ph.D., is the president of Quaestio Global
       Partners LLC (Quaestio GP), as the Director, Global External
       Opportunities, Pfizer Consumer Healthcare, Morris Plains, NJ.
       Dr. Abdel-Malik identified and secured external products and
       technologies achieving above-market growth for the $4B Pfizer Consumer
       Healthcare business.
    c. Thomas G. Hartman, Ph.D. has served for the past 22 years as Mass
       Spectrometry Lab Manager at the Rutgers University Center for Advanced
       Food Technology (CAFT). Dr. Hartman has served as an analytical and
       technical consultant to over 250 companies and many government
       agencies. He is a member of the American Society of Mass Spectrometry
       (ASMS), American Chemical Society (ACS) and the Agricultural and Food
       Chemistry Division, American Association for the Advancement of
       Science (AAAS) and Institute of Food Technologists (IFT).
    d. Demian Barbas B.Sc., Ph.D., has particular expertise in biochemistry,
       biotechnology, intellectual property law and patents in life sciences.
       Dr. Barbas is currently practising at Ogilvy Renault LLP/S.E.N.C.R.L.,
       s.r.l., and is a member of the American Society for Biochemistry and
       Molecular Biology (ASBMB) and an affiliate of the Intellectual
       Property Institute of Canada (IPIC).
    e. Melvin Dionne B.Sc. Pharm., has been the president of Services
       Pharmaceutiques Melvin Dionne Inc since 1999. He has a strong
       background in regulatory affairs and quality control in the
       pharmaceutical industry, with particular expertise in pharmaceutical
       company compliance with Health Canada and FDA regulations for product
       and site licensing.

    "I feel extremely honoured to be working with such an eminent group of
scientists and profiting from their guidance and valuable advice while
developing and building our product pipeline and growing in the nutraceutical
and pharmaceutical worlds" said Dr. Tina Sampalis, Vice-President Research and
Business Development of Neptune.

    About Neptune Technologies & Bioressources Inc.

    Neptune Technologies & Bioressources Inc. develops proprietary and potent
health ingredients from underexploited marine biomasses, such as krill, with
its patented extraction process (Neptune OceanExtract(TM)). Using its
proprietary process, Neptune Technologies & Bioressources Inc. is
strategically positioning itself in the nutraceutical and pharmaceutical
health and wellness market. The Company develops and markets new formulas and
new products for specific applications in high growth markets such the
nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets, the
next wave in nutritional research. Through strategic alliances and
partnerships, as well as through clinical studies, the Company continues to
demonstrate the immense beneficial effects of these products.

    The TSX.V has not reviewed and does not accept responsibility for the
                 adequacy and accuracy of this news release.
    

    Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of the Company to be materially
different from the historical results, from any future results expressed, or
implied by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein are also
subject generally to other risks and uncertainties that are described from
time to time in the Company's reports and registration statements filed with
the Securities and Exchange Commission.




For further information:

For further information: US Contact: John Tsemberides, ROI Group LLC,
(212) 495-0743, john@roiny.com; Canada Contact: Grant Howard, The Howard
Group, Toll free: 888-221-0915, infor@howardgroupinc.com,
www.howardgroupinc.com; Company Contact: André Godin, V.P Administration and
Finance, Neptune Technologies & Bioressources Inc.,
a.godin@neptunebiotech.com, www.neptunebiotech.com

Organization Profile

Neptune Technologies and Bioressources Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890